Fintel reports that on February 28, 2025, Seaport Global downgraded their outlook for Array Technologies (NasdaqGM:ARRY) from Buy to Neutral. Analyst Price Forecast Suggests 60.27% Upside As of ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings ...

In this article, we are going to take a look at where Array Technologies, Inc. (NASDAQ:ARRY) stands against the other solar stocks. Solar electricity is a renewable energy source that is produced ...

In a report released today, Jordan Levy from Truist Financial maintained a Buy rating on Array Technologies (ARRY – Research Report). The company’s shares closed yesterday at $6.55.

Shares of solar tracking systems manufacturer Array (NASDAQ:ARRY) fell 21.4% in the afternoon session after the company reported weaker than expected fourth quarter 2024 results, with EBITDA missing ...

2025 Free Cash Flow Guidance: $115 to $130 million. Array Technologies Inc (NASDAQ:ARRY) reported strong financial results for the fourth quarter and full year 2024, with revenue exceeding the ...

Array Technologies, Inc. (ARRY) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.21 per share a year ago.

Solar tracking systems manufacturer Array (NASDAQ:ARRY) will be reporting earnings tomorrow after market close. Here’s what to look for. Array met analysts’ revenue expectations last quarter ...

What is the Price to Earnings Growth (PEG) Ratio? The PEG Ratio chart for Array Biopharma (ARRY) compares PE to EPS Growth rates. Defining fair value is the goal of measuring valuation using the PEG ...

What is a PE Ratio? The PE Ratio chart for Array Biopharma (ARRY) is a valuation observation. A PE Ratio is a price to earnings ratio that has historically helped investors define fair value. This is ...